National Health Investors (NHI) Misses Q4 FFO Estimates

Thursday, Feb 26, 2026 7:02 pm ET3min read
NHI--
Aime RobotAime Summary

- National Health Investors (NHI) reported Q4 FFO of $1.22/share, missing Zacks' $1.24 estimate but exceeding prior-year results.

- Quarterly revenue reached $105.82M, surpassing estimates by 7.08%, with three of four quarters exceeding consensus revenue forecasts.

- Shares gained 15.4% YTD vs. S&P 500's 1.5%, supported by a Zacks Rank #2 (Buy) rating based on favorable estimate revisions.

National Health Investors (NHI) came out with quarterly funds from operations (FFO) of $1.22 per share, missing the Zacks Consensus Estimate of $1.24 per share. This compares to FFO of $1.13 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an FFO surprise of -1.21%. A quarter ago, it was expected that this health care real estate investment trust would post FFO of $1.24 per share when it actually produced FFO of $1.32, delivering a surprise of +6.45%.

Over the last four quarters, the company has surpassed consensus FFO estimates three times.

National Health Investors, which belongs to the Zacks REIT and Equity Trust - Other industry, posted revenues of $105.82 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 7.08%. This compares to year-ago revenues of $85.75 million. The company has topped consensus revenue estimates three times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future FFO expectations will mostly depend on management's commentary on the earnings call.

National Health Investors shares have added about 15.4% since the beginning of the year versus the S&P 500's gain of 1.5%.

What's Next for National Health Investors?

While National Health Investors has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's FFO outlook. Not only does this include current consensus FFO expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of estimate revisions.

Ahead of this earnings release, the estimate revisions trend for National Health Investors was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus FFO estimate is $1.21 on $102.28 million in revenues for the coming quarter and $5.12 on $422.04 million in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, REIT and Equity Trust - Other is currently in the bottom 38% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Jefferies (JEF), another stock in the broader Zacks Finance sector, has yet to report results for the quarter ended February 2026.

This investment banking and capital markets company is expected to post quarterly earnings of $1.15 per share in its upcoming report, which represents a year-over-year change of +91.7%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Jefferies' revenues are expected to be $2.15 billion, up 34.8% from the year-ago quarter.

Should You Invest in National Health Investors, Inc. (NHI)?

Before you invest in National Health Investors, Inc. (NHI), want to know the best stocks to buy for the next 30 days? Check out Zacks Investment Research for our free report on the 7 best stocks to buy.

Zacks Investment Research has been committed to providing investors with tools and independent research since 1978. For more than a quarter century, the Zacks Rank stock-rating system has more than doubled the S&P 500 with an average gain of +24.08% per year. (These returns cover a period from January 1, 1988 through May 6, 2024.)

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report



National Health Investors, Inc. (NHI): Free Stock Analysis Report

Jefferies Financial Group Inc. (JEF): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

Zacks is the leading investment research firm focusing on equities earnings estimates and stock analysis for the individual investor, including stock picks, stock screening, portfolio stock tracker and stock screeners. Copyright 2006-2026 Zacks Equity Research, Inc. editor@zacks.com (Manaing editor) webmaster@zacks.com (Webmaster)

Latest Articles

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet